Petros Pharmaceuticals Inc (PTPI)

Apr 24, 2025, 9:01 AM EDT - 4 days ago

NextTrip Provides Business Update and Highlights Major Milestones in Strategic Expansion, Solidifying Positioning in Luxury and Experiential Travel

NTRP

Apr 14, 2025, 8:45 AM EDT - 14 days ago

NextTrip Completes Full Acquisition of Luxury Travel Brand Five Star Alliance with Remaining 51% Purchase

NTRP

Apr 7, 2025, 9:01 AM EDT - 21 days ago

NextTrip Acquires JOURNY TV Channel, Expanding Its FAST Media Footprint

NTRP

Apr 3, 2025, 9:01 AM EDT - 25 days ago

NextTrip Holdings and Intimate Hotels of Barbados Forge Strategic Partnership to Enhance Caribbean Travel Experience

NTRP

Apr 1, 2025, 9:01 AM EDT - 27 days ago

NextTrip Reports Strong Growth in Group Bookings Following Five Star Alliance Collaboration

NTRP

Mar 27, 2025, 9:01 AM EDT - 4 weeks ago

NextTrip Launches New Innovative Online Cruise Booking Platform NextTrip Cruise

NTRP

Mar 20, 2025, 9:15 AM EDT - 5 weeks ago

Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications

Feb 28, 2025, 9:01 AM EST - 2 months ago

NextTrip Strengthens Financial Position with the Conversion of $2.6 Million in Short-Term Debt to Restricted Equity Before its Fiscal Year-End

NTRP

Feb 27, 2025, 9:01 AM EST - 2 months ago

NextTrip and Blue Fysh Announce Strategic Partnership and Share Exchange Agreement to Drive Mutual Growth

NTRP

Feb 25, 2025, 9:20 AM EST - 2 months ago

Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study

Feb 25, 2025, 9:01 AM EST - 2 months ago

NextTrip Appoints John McMahon as Chief Operating Officer - Travel, Expands into Cruise Industry with Five Star Alliance

NTRP

Feb 18, 2025, 9:25 AM EST - 2 months ago

Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants

Feb 11, 2025, 8:50 AM EST - 2 months ago

NextTrip Closes on 49% Stake in Five Star Alliance

NTRP

Feb 6, 2025, 4:30 PM EST - 2 months ago

NextTrip Invests in Luxury Travel Brand Five Star Alliance to secure 49% Stake with an Option to Purchase a Controlling Interest

NTRP

Jan 7, 2025, 9:15 AM EST - 3 months ago

Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules

Dec 19, 2024, 9:15 AM EST - 4 months ago

Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”

Dec 17, 2024, 9:00 AM EST - 4 months ago

Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

Dec 3, 2024, 9:01 AM EST - 5 months ago

NextTrip Launches Advertising on Compass.tv in Collaboration with Leap Media Group

NTRP

Nov 5, 2024, 9:01 AM EST - 6 months ago

NextTrip Plans to Acquire Luxury Travel Company Five Star Alliance

NTRP

Oct 1, 2024, 9:02 AM EDT - 7 months ago

NextTrip Prepares Compass.tv for Soft Launch, Signs New Content Creators

NTRP

Sep 11, 2024, 9:15 AM EDT - 8 months ago

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Sep 3, 2024, 9:00 AM EDT - 8 months ago

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Jul 30, 2024, 9:01 AM EDT - 9 months ago

NextTrip Introduces Group Booking Technology Platform to Streamline and Simplify Travel for Groups

NTRP

Jul 29, 2024, 9:20 AM EDT - 9 months ago

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Jul 19, 2024, 5:00 PM EDT - 10 months ago

NextTrip, Inc. Receives Nasdaq Notification Regarding Late 10-Q Filing and Continued Listing Requirements

NTRP

Jul 18, 2024, 9:08 AM EDT - 10 months ago

NextTrip Taps Dooya Media Group To Launch Compass.TV

NTRP

Jul 16, 2024, 9:00 AM EDT - 10 months ago

Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

Jul 11, 2024, 9:01 AM EDT - 10 months ago

NextTrip Launches FlexPay Travel Payment Options for Bookings

NTRP

Jun 21, 2024, 5:00 PM EDT - 11 months ago

NextTrip, Inc Receives Nasdaq Notification Regarding Late 10K Filing and Continued Listing Requirements

NTRP

May 14, 2024, 9:15 AM EDT - 1 year ago

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe

Apr 23, 2024, 9:15 AM EDT - 1 year ago

Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health

Apr 16, 2024, 9:15 AM EDT - 1 year ago

Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)

Apr 2, 2024, 9:15 AM EDT - 1 year ago

Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status

Apr 2, 2024, 9:01 AM EDT - 1 year ago

NextTrip Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program

NTRP

Mar 19, 2024, 9:00 AM EDT - 1 year ago

Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider

Feb 14, 2024, 9:15 AM EST - 1 year ago

Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider

Jan 24, 2024, 9:15 AM EST - 1 year ago

Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch

Jan 17, 2024, 9:00 AM EST - 1 year ago

Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch

Dec 12, 2023, 10:00 AM EST - 1 year ago

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status

Dec 12, 2023, 9:15 AM EST - 1 year ago

Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider

Oct 30, 2023, 9:15 AM EDT - 1 year ago

Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)

Oct 19, 2023, 9:00 AM EDT - 1 year ago

Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

Oct 4, 2023, 9:00 AM EDT - 1 year ago

Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label

Sep 28, 2023, 8:00 AM EDT - 1 year ago

Petros Pharmaceuticals to Present at the LD Micro Main Event XVI

Sep 11, 2023, 9:00 AM EDT - 1 year ago

Petros Pharmaceuticals Provides Letter to Shareholders

Sep 6, 2023, 4:05 PM EDT - 1 year ago

Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Jul 13, 2023, 4:30 PM EDT - 1 year ago

Petros Pharmaceuticals Announces Capital Raise of $15 Million

Nov 30, 2022, 12:45 PM EST - 2 years ago

Petros Pharmaceuticals Announces Reverse Stock Split

Nov 15, 2022, 8:00 AM EST - 2 years ago

Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update

Oct 25, 2022, 9:00 AM EDT - 2 years ago

New FDA-Approved Labeling for Petros Pharmaceuticals' STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy